Moderna Statistics
Total Valuation
Moderna has a market cap or net worth of $20.29 billion. The enterprise value is $13.46 billion.
Important Dates
The next estimated earnings date is Thursday, April 30, 2026, before market open.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Moderna has 394.94 million shares outstanding. The number of shares has increased by 1.30% in one year.
| Current Share Class | 396.59M |
| Shares Outstanding | 394.94M |
| Shares Change (YoY) | +1.30% |
| Shares Change (QoQ) | +0.51% |
| Owned by Insiders (%) | 6.63% |
| Owned by Institutions (%) | 80.58% |
| Float | 369.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.44 |
| Forward PS | 10.26 |
| PB Ratio | 2.34 |
| P/TBV Ratio | 2.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 6.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.29, with a Debt / Equity ratio of 0.15.
| Current Ratio | 3.29 |
| Quick Ratio | 3.06 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -307.40 |
Financial Efficiency
Return on equity (ROE) is -28.87% and return on invested capital (ROIC) is -63.28%.
| Return on Equity (ROE) | -28.87% |
| Return on Assets (ROA) | -14.51% |
| Return on Invested Capital (ROIC) | -63.28% |
| Return on Capital Employed (ROCE) | -29.70% |
| Weighted Average Cost of Capital (WACC) | 11.01% |
| Revenue Per Employee | $413,617 |
| Profits Per Employee | -$600,426 |
| Employee Count | 4,700 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 29.63 |
Taxes
In the past 12 months, Moderna has paid $54.00 million in taxes.
| Income Tax | 54.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +54.20% in the last 52 weeks. The beta is 1.35, so Moderna's price volatility has been higher than the market average.
| Beta (5Y) | 1.35 |
| 52-Week Price Change | +54.20% |
| 50-Day Moving Average | 47.06 |
| 200-Day Moving Average | 32.47 |
| Relative Strength Index (RSI) | 51.65 |
| Average Volume (20 Days) | 9,491,456 |
Short Selling Information
The latest short interest is 70.23 million, so 17.78% of the outstanding shares have been sold short.
| Short Interest | 70.23M |
| Short Previous Month | 71.34M |
| Short % of Shares Out | 17.78% |
| Short % of Float | 18.98% |
| Short Ratio (days to cover) | 6.63 |
Income Statement
In the last 12 months, Moderna had revenue of $1.94 billion and -$2.82 billion in losses. Loss per share was -$7.25.
| Revenue | 1.94B |
| Gross Profit | -2.06B |
| Operating Income | -3.07B |
| Pretax Income | -2.77B |
| Net Income | -2.82B |
| EBITDA | -2.86B |
| EBIT | -3.07B |
| Loss Per Share | -$7.25 |
Full Income StatementBalance Sheet
The company has $5.80 billion in cash and $1.31 billion in debt, with a net cash position of $6.83 billion or $17.29 per share.
| Cash & Cash Equivalents | 5.80B |
| Total Debt | 1.31B |
| Net Cash | 6.83B |
| Net Cash Per Share | $17.29 |
| Equity (Book Value) | 8.65B |
| Book Value Per Share | 21.95 |
| Working Capital | 4.56B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$1.87 billion and capital expenditures -$192.00 million, giving a free cash flow of -$2.07 billion.
| Operating Cash Flow | -1.87B |
| Capital Expenditures | -192.00M |
| Depreciation & Amortization | 215.00M |
| Net Borrowing | 582.00M |
| Free Cash Flow | -2.07B |
| FCF Per Share | -$5.23 |
Full Cash Flow StatementMargins
Gross margin is -105.76%, with operating and profit margins of -158.13% and -145.16%.
| Gross Margin | -105.76% |
| Operating Margin | -158.13% |
| Pretax Margin | -142.39% |
| Profit Margin | -145.16% |
| EBITDA Margin | -147.07% |
| EBIT Margin | -158.13% |
| FCF Margin | n/a |
Dividends & Yields
Moderna does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.30% |
| Shareholder Yield | -1.30% |
| Earnings Yield | -13.91% |
| FCF Yield | -10.18% |
Dividend DetailsAnalyst Forecast
The average price target for Moderna is $33.00, which is -35.77% lower than the current price. The consensus rating is "Hold".
| Price Target | $33.00 |
| Price Target Difference | -35.77% |
| Analyst Consensus | Hold |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 29.05% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Moderna has an Altman Z-Score of 2.44 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.44 |
| Piotroski F-Score | 1 |
